Dermata Therapeutics, Inc.
corporate_fare Company Profile
Dermata Therapeutics, Inc. (NASDAQ:DRMA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 24 items for DRMA at importance 7 or higher on its 1–10 market-impact scale.
Recent high-impact activity:
- Dermata Therapeutics Changes Independent Auditor, Appointing Former Firm CBIZ CPAs
- Dermata Therapeutics Finalizes Resale Prospectus for 6.2M Shares and Warrants, Securing Potential $8.6M Capital
- Dermata Therapeutics Updates At-The-Market Offering Capacity to $705,000
- Dermata Therapeutics CEO Gerald Proehl Invests $1.25M in Private Placement, Increasing Stake to 24.7%
Financial Snapshot
Fiscal year ended December 31, 2025
Net Income
-$7.56M
Diluted EPS
-$8.16
Op. Cash Flow
-$7.76M
Operating Income
-$7.77M
Cash & Equivalents
$7.52M
Debt / Equity
0.00×
Shares Outstanding
2.66M sh
Source: 10-K · filed 2026-03-26 · accession 0001493152-26-012992
show_chartPrice Chart
Loading chart...
feed DRMA - Filings & News (Page 2)
DRMA
Feb 03, 2026, 4:05 PM EST
Price at Filing:
$1.90
Real-time Price:
$0.510
Change:
-$1.39 (-73%)
Market Cap:
$2.512M
DRMA
Jan 29, 2026, 5:12 PM EST
Price at Filing:
$2.86
Real-time Price:
$0.510
Change:
-$2.35 (-82%)
Market Cap:
$2.512M
DRMA
Jan 27, 2026, 8:00 AM EST
Price at Filing:
$3.02
Real-time Price:
$0.510
Change:
-$2.51 (-83%)
Market Cap:
$2.512M
DRMA
Jan 08, 2026, 4:05 PM EST
Price at Filing:
$2.14
Real-time Price:
$0.510
Change:
-$1.63 (-76%)
Market Cap:
$2.512M